Geron (NASDAQ: GERN) stock is getting crushed in Wednesday's trading. The company's share price was down 31.7% as of 3:50 p.m ...

Geron Corporation's stock dropped 50% before its Q4 2024 earnings report, with Rytelo's revenue close to projections but new ...

Wedbush is removing Geron (GERN) from the firm’s Best Ideas List due to its investment price discipline. Wedbush has an Outperform rating on ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...

Hello and welcome to the Geron fourth quarter and full year 2024 earnings call. All lines have been placed on mute to prevent ...

Barclays analyst Peter Lawson lowered the firm’s price target on Geron (GERN) to $4 from $9 and keeps an Overweight rating on the shares post ...

Geron shares fell 30% to $1.66 after the company reported a fourth-quarter loss that was wider than expected.

John Scarlett; Chairman of the Board, President, Chief Executive Officer; Geron Corp Jim Ziegler; Executive Vice President, Chief Commercial Officer; Geron Corp Joseph Eid; Executive Vice President- ...

B. Riley dropped their FY2025 earnings per share (EPS) estimates for shares of Geron in a research report issued to clients ...

FOSTER CITY, Calif. (AP) — FOSTER CITY, Calif. (AP) — Geron Corp. (GERN) on Wednesday reported a loss of $25.4 million in its fourth quarter. The Foster City, California-based company said it had a ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to p ...